SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- February 20, 2007 -- Theravance, Inc. (NASDAQ: THRX) announced today that the U.S. Food & Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational antibiotic telavancin for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). The FDA has established a goal of a standard ten-month review of the telavancin NDA. The NDA filing triggers a milestone payment of $31 million from Theravance’s partner, Astellas Pharma Inc.
